Pharmafile Logo
Pharmafocus logo
Advanced Search

Roche

Showing 15 posts of 710 posts found.

thumbs_up

AbbVie/Roche gain FDA approval for blockbuster treatment

June 11, 2018
Sales and Marketing AbbVie, Roche, biotech, drugs, pharma, pharmaceutical

AbbVie and Roche have a chalked up a major success, after the FDA gave its approval for Venclexta, in combination …

News
roche

Roche’s breast, lung cancer offerings fail to impress at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq

Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …

News
roche_side_building

Roche resigns itself to failure on SMA drug

June 1, 2018
Medical Communications Roche, biotech, drugs, pharma, pharmaceutical, spinal muscular atrophy

Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after …

News

Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3

May 29, 2018
Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …

News
jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

News
prothena-37882-2

Prothena guts workforce by more than half, after trial failure

May 25, 2018
Medical Communications Neil Woodford, Prothena, Roche, biotech, drugs, pharma, pharmaceutical

Prothena Therapeutics has acted drastically by slashing staff numbers by more than half, after the failure of two pivotal trials …

News
roche

Roche’s Hemlibra stakes claim to be haemophilia market leader

May 21, 2018
Research and Development, Sales and Marketing Hemlibra, Roche, Shire, biotech, drugs, haemophilia, pharma, pharmaceutical

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …

News

Study finds Herceptin use can be halved

May 17, 2018
Medical Communications, Research and Development Herceptin, Roche, biosimilars, biotech, drugs, pharma, pharmaceutical

A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …

News
roche_close

Roche gets NICE approval for advanced bladder cancer

May 17, 2018
Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical, tecentriq

Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment …

News
roche

Roche’s Tecentriq/Cotellic combo therapy fails to impress in colorectal cancer

May 11, 2018
Medical Communications, Research and Development Cancer, Cotellic, Roche, pharma, tecentriq

Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people …

News
soil-3301161_960_720

Lodo and Roche go digging for drug candidates, after $1bn deal

May 10, 2018
Sales and Marketing Genentech, Roche, biotech, drugs, pharma, pharmaceutical

Discovering potential therapeutics from natural sources has been a constant throughout the evolution of medicine, Lodo Therapeutics, however, has taken …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

News

EMA’s CHMP backs Roche’s Perjeta combo in HER2-positive breast cancer

April 30, 2018
Sales and Marketing Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma

Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s Committee for Medicinal Products …

News
john_reed

Sanofi makes ex-Roche scientist new R&D chief

April 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Sanofi, appointment, pharma

With the retirement of Elias Zerhouni as Head of Global R&D, Sanofi had to find a suitable replacement and believes …

Appointment
john_reed

Sanofi makes ex-Roche scientist new R&D chief

April 25, 2018
Medical Communications, Research and Development Roche, Sanofi, biotech, drugs, pharma, pharmaceutical

With the retirement of Elias Zerhouni as Head of Global R&D, Sanofi had to find a suitable replacement and believes …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025